Free Trial

Tempest Therapeutics (TPST) News Today

$2.03
+0.02 (+1.00%)
(As of 06/21/2024 ET)
Why Is Tempest Therapeutics (TPST) Stock Up 45% Today?
Tempest Therapeutics, Inc. (NASDAQ:TPST) Sees Significant Increase in Short Interest
Tempest Therapeutics, Inc. (NASDAQ:TPST - Get Free Report) was the target of a large growth in short interest in April. As of April 30th, there was short interest totalling 1,580,000 shares, a growth of 39.8% from the April 15th total of 1,130,000 shares. Based on an average daily trading volume, of 901,800 shares, the short-interest ratio is presently 1.8 days. Currently, 9.4% of the company's stock are sold short.
Tempest Therapeutics' (TPST) "Buy" Rating Reiterated at HC Wainwright
HC Wainwright restated a "buy" rating and set a $47.00 price objective on shares of Tempest Therapeutics in a research report on Friday.
TPST Stock Earnings: Tempest Therapeutics Beats EPS for Q1 2024
Tempest Therapeutics, Inc. (NASDAQ:TPST) Short Interest Update
Tempest Therapeutics, Inc. (NASDAQ:TPST - Get Free Report) was the target of a significant growth in short interest in March. As of March 31st, there was short interest totalling 969,700 shares, a growth of 26.5% from the March 15th total of 766,800 shares. Currently, 6.1% of the shares of the stock are short sold. Based on an average daily volume of 1,030,000 shares, the short-interest ratio is currently 0.9 days.
Tempest Therapeutics (NASDAQ:TPST) Trading Down 6.8%
Tempest Therapeutics (NASDAQ:TPST) Stock Price Down 6.8%
Q3 2024 Earnings Estimate for Tempest Therapeutics, Inc. (NASDAQ:TPST) Issued By HC Wainwright
Tempest Therapeutics, Inc. (NASDAQ:TPST - Free Report) - Investment analysts at HC Wainwright issued their Q3 2024 earnings per share estimates for Tempest Therapeutics in a report released on Wednesday, March 20th. HC Wainwright analyst J. Pantginis expects that the company will post earnings of
Research Analysts Issue Forecasts for Tempest Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:TPST)
Tempest Therapeutics, Inc. (NASDAQ:TPST - Free Report) - Equities researchers at HC Wainwright issued their Q1 2024 earnings per share estimates for shares of Tempest Therapeutics in a research report issued on Wednesday, March 20th. HC Wainwright analyst J. Pantginis forecasts that the company w
Piper Sandler Keeps Their Buy Rating on Tempest Therapeutics (TPST)
William Blair Reiterates "Outperform" Rating for Tempest Therapeutics (NASDAQ:TPST)
William Blair reaffirmed an "outperform" rating on shares of Tempest Therapeutics in a research report on Wednesday.
Tempest Therapeutics, Inc. (NASDAQ:TPST) Short Interest Down 17.7% in February
Tempest Therapeutics, Inc. (NASDAQ:TPST - Get Free Report) was the recipient of a significant decrease in short interest in the month of February. As of February 29th, there was short interest totalling 716,500 shares, a decrease of 17.7% from the February 14th total of 870,400 shares. Approximately 4.5% of the shares of the stock are sold short. Based on an average daily volume of 886,000 shares, the short-interest ratio is presently 0.8 days.
Tempest Therapeutics (NASDAQ:TPST) Research Coverage Started at Scotiabank
Scotiabank initiated coverage on shares of Tempest Therapeutics in a report on Thursday. They issued a "sector outperform" rating and a $13.00 target price for the company.
Tempest Therapeutics (NASDAQ:TPST) Shares Down 4.9%
Tempest Therapeutics (NASDAQ:TPST) Stock Price Down 4.9%
Tempest Therapeutics logo with medical background
Tempest Therapeutics (NASDAQ:TPST) Receives New Coverage from Analysts at Jefferies Financial Group
Jefferies Financial Group started coverage on Tempest Therapeutics in a report on Thursday. They set a "buy" rating and a $15.00 price target on the stock.
Tempest Therapeutics (NASDAQ:TPST) Shares Down 0.7%
Tempest Therapeutics (NASDAQ:TPST) Shares Down 0.7%
Tempest Therapeutics, Inc. (TPST)
Get Tempest Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter.

Gold Set to EXPLODE! (Ad)

The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing demand from Central Banks and billionaires to EXPLODE! The elites are buying up gold like nothing we've seen before…

Click here now to download the free Precious Metals Buying Guide.

TPST Media Mentions By Week

TPST Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

TPST
News Sentiment

-0.03

0.71

Average
Medical
News Sentiment

TPST News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

TPST Articles
This Week

7

2

TPST Articles
Average Week

Get Tempest Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:TPST) was last updated on 6/23/2024 by MarketBeat.com Staff

From Our Partners